Department of Anesthesiology and Pain Relief, National Cancer Institute, Cairo University, Cairo.
Department of Anesthesia, ICU, and Pain Management, Faculty of Medicine, Ain Shams University, El rehab city, Egypt.
Clin J Pain. 2019 Mar;35(3):247-251. doi: 10.1097/AJP.0000000000000673.
The objective of this study was to investigate the effects of the preoperative combination of oral Pregabalin and intravenous (IV) magnesium sulfate as analgesic adjuvants in postthoracotomy pain.
One hundred twenty patients with American Society of Anesthesiologists physical status II were allocated randomly into 1 of 4 groups. Group MP received 300 mg pregabalin orally and an IV infusion of magnesium sulfate 50 mg/kg mixed with 200 mL normal saline (NS); group P received 300 mg pregabalin orally and 200 mL NS infusion; group M received an IV infusion of magnesium sulfate 50 mg/kg mixed with 200 mL NS and a placebo capsule; and group C received placebo capsule and an IV infusion of 200 mL NS. All medications were given 1 hour before surgery in all groups. In the first 24 hours postoperatively, total morphine consumption, the Visual Analog Scale (0 to 10)-used as a pain measurement tool-and postoperative nausea and vomiting were assessed.
The total morphine consumption in the first 24 hours postoperatively decreased significantly in group MP (28.47±5.76 mg) compared with group P (33.97±6.34 mg), group M (40.87±4.4 mg), and group C (42.2±6.1 mg), respectively. VAS scores were in the accepted range (≤4) in the 4 groups throughout the first 24 hours, as all patients were on patient-controlled analgesia. However, there was a statistically significant difference at 0 and 4 hours postoperatively in favor of groups MP and P. Postoperative nausea and vomiting decreased significantly in groups MP, P, and M in comparison with group C (P<0.001).
The combined preoperative single dose of pregabalin and magnesium sulfate is an effective method for attenuating postoperative pain and total morphine consumption in patients undergoing thoracotomy.
本研究旨在探讨术前联合应用口服普瑞巴林和静脉注射(IV)硫酸镁作为镇痛佐剂对开胸术后疼痛的影响。
120 名美国麻醉医师协会身体状况 II 级的患者被随机分为 4 组。MP 组患者口服 300mg 普瑞巴林,并静脉输注 50mg/kg 硫酸镁混合 200mL 生理盐水(NS);P 组患者口服 300mg 普瑞巴林,静脉输注 200mL NS;M 组患者静脉输注 50mg/kg 硫酸镁混合 200mL NS 和安慰剂胶囊;C 组患者给予安慰剂胶囊和静脉输注 200mL NS。所有药物均在所有组患者术前 1 小时给予。在术后 24 小时内,评估总吗啡用量、视觉模拟评分(0 到 10 分)作为疼痛测量工具以及术后恶心和呕吐。
与 P 组(33.97±6.34mg)、M 组(40.87±4.4mg)和 C 组(42.2±6.1mg)相比,MP 组(28.47±5.76mg)术后 24 小时内总吗啡用量明显减少。在 4 组中,VAS 评分在整个 24 小时内均处于可接受的范围内(≤4),因为所有患者均接受患者自控镇痛。然而,在术后 0 小时和 4 小时,MP 组和 P 组有统计学意义上的差异。与 C 组相比,MP 组、P 组和 M 组的术后恶心和呕吐明显减少(P<0.001)。
术前单次联合应用普瑞巴林和硫酸镁是减轻开胸术后疼痛和总吗啡用量的有效方法。